Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ZUCLOPENTHIXOL DIHYDROCHLORIDE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N05A, N05AF) — coverage varies; not interchangeable

  • Flupentixol decanoate (Fluanxol Depot): general benefit
  • Flupentixol (Fluanxol): general benefit
  • Zuclopenthixol decanoate (Clopixol Depot): general benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Clopixol · DIN 02230402 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Clopixol · DIN 02230402 Manufacturer: Lundbeck Canada Inc.; listing date 2017-12-21 Health Canada: Marketed since 1997-05-02 · brand CLOPIXOL · ATC N05AF05 ZUCLOPENTHIXOL · form Tablet · route Oral · ingredients ZUCLOPENTHIXOL (ZUCLOPENTHIXOL HYDROCHLORIDE) 10 MG · company Lundbeck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Clopixol: Formulary list price $0.5592/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5592 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49241 · Verify on the e-Formulary ↗ (DIN 02230402)

Source record
DIN 02230402: Clopixol Raw flags: sec3=Y Item: 281608184; group id 511; item number 1350; lccId None; manufacturer id VLH Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.5592; ministry $0.5592 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230402 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49241
Shortage status: resolved shortage (ended 2022-03-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230402
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clopixol · DIN 02230403 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Clopixol · DIN 02230403 Manufacturer: Lundbeck Canada Inc.; listing date 2017-12-21 Health Canada: Marketed since 1997-05-02 · brand CLOPIXOL · ATC N05AF05 ZUCLOPENTHIXOL · form Tablet · route Oral · ingredients ZUCLOPENTHIXOL (ZUCLOPENTHIXOL HYDROCHLORIDE) 25 MG · company Lundbeck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Clopixol: Formulary list price $1.3979/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3979 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49242 · Verify on the e-Formulary ↗ (DIN 02230403)

Source record
DIN 02230403: Clopixol Raw flags: sec3=Y Item: 281608183; group id 511; item number 1351; lccId None; manufacturer id VLH Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $1.3979; ministry $1.3979 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230403 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49242
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230403
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

ZUCLOPENTHIXOL DECANOATE

· 1 products · General benefit · strengths: 200mg/mL · Inj-1mL Pk

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

LURASIDONE HYDROCHLORIDE

· 38 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) · strengths: 20mg, 40mg, 60mg, 80mg, 120mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the manifestations of schizophrenia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ZUCLOPENTHIXOL DECANOATE LURASIDONE HYDROCHLORIDE · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) INDICATIONS AND CLINICAL USE Adults Schizophrenia Taro-Lurasidone (lurasidone hydrochloride tablets) is indicated for the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00065650.PDF; date not captured; DIN 02504499; fetched 2026-09-10 Product monograph QUETIAPINE · General benefit (125), Off-Formulary Interchangeable, not an ODB benefit (3) INDICATIONS Schizophrenia SEROQUEL (quetiapine fumarate immediate-release) is indicated for: • the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00078929.PDF; date MAR 18, 2025; DIN 02236951; fetched 2026-09-10 Product monograph ZUCLOPENTHIXOL DECANOATE · General benefit Indications CLOPIXOL (zuclopenthixol hydrochloride), CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) and CLOPIXOL DEPOT (zuclopenthixol decanoate injection) are indicated for: • the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230406; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications CLOPIXOL (zuclopenthixol hydrochloride), CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) and CLOPIXOL DEPOT (zuclopenthixol decanoate injection) are indicated for: • the management of the manifestations of schizophrenia. CLOPIXOL (zuclopenthixol tablets as zuclopenthixol hydrochloride) may be used during initial treatment and for maintenance treatment. CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) is intended for the initial treatment of acute psychotic episodes or exacerbation of psychosis associated with schizophrenia. CLOPIXOL DEPOT (zuclopenthixol decanoate injection) is intended for maintenance treatment. 1.1. Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of CLOPIXOL, CLOPIXOL ACUPHASE and CLOPIXOL DEPOT in pediatric patients under the age of 18 years have not been established, therefore Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2. Geriatrics Geriatrics (> 65 years of age): The pharmacokinetics, safety, and efficacy of CLOPIXOL, CLOPIXOL ACUPHASE and CLOPIXOL DEPOT in geriatric patients with schizophrenia have not been systematically evaluated in clinical trials. Caut… https://pdf.hres.ca/dpd_pm/00085236.PDF PM date: 2026-06-30 Source product: CLOPIXOL; DIN 02230402; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.